Outcome of Intravitreal Dexamethasone Implant Use in Uveitic Eyes Undergoing Pars Plana Vitrectomy Surgery. (18th August 2021)

• Record Type: Journal Article
• Authors: Kirkland, Kyle A.; Uwaydat, Sami H.; Siddiqui, Mohammad Z.; Chancellor, John R.; Soliman, Mohamed K.; Kurup, Shree; Sallam, Ahmed B.
• Is Part Of: Ocular immunology and inflammation. Volume 29:Number 6(2021)
• Page Start: 1126
• Page End: 1131
• Publication Date: 2021-08-18
• Subjects: Dexamethasone Implant -- uveitis -- vitrectomy -- PPV; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2020.1726970
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : To report the outcomes in eyes with noninfectious uveitis receiving dexamethasone implant at the time of pars plana vitrectomy (PPV). Methods : Retrospective analysis of visual acuity (VA), intraocular pressure (IOP), vitreous haze score (VHS), and central subfield thickness (CST) at baseline and follow-up visits. Results : Fourteen eyes received dexamethasone implant at the time of PPV. The CST was improved from 469 ± 182 µm at baseline to 320 ± 60 at 6 months ( p = .0112) and 295 ± 46 at 12 months ( p = .0728). Vitritis only recurred in 2 eyes at 6 months (18.2%) and 1 eye at 12 months (14.3%). The probability of VA improvement of ≥0.3 logMAR was 57% at 6 months and 66% at 12 months. Therapy for IOP rise was initiated in 6 eyes (42.9%). Conclusions : Local delivery of dexamethasone implant with PPV is a feasible method to counteract postoperative inflammation and macular thickening.